A Real-world Study to Investigate Cardiovascular Risk Profile Among Newly Diagnosed Type 2 Diabetes Mellitus (T2DM) Participants

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age40-70
SponsorNovo Nordisk A/S

About this trial

The purpose of the study is to investigate the cardiovascular disease (CVD) risk profile among participants newly diagnosed with type 2 diabetes mellitus (T2DM) in Southeast Asia (CRISTAL SEA). It's a retrospective chart-review across five Southeast Asian countries to characterize newly diagnosed T2DM participants and how their CVD risk is distributed, using data from the year before diagnosis and roughly the first year after diagnosis.

Eligibility criteria

Qualifiers

Aged greater than equal to (≥) 40 and less than (<) 70 years

Male or female

Newly diagnosed with T2DM and initiated on anti-hyperglycemic treatment between 1 January 2022 and 31 December 2023

Disqualifiers

If any exclusion criterion is met, the participant will be excluded from the study.

T1DM or gestational diabetes

Prescribed with any anti-hyperglycemic medications before first diagnosis of T2DM

Pregnant women

Trial design

Treatments tested in this trial

  • No treatment given

Treatment groups

400 Participants
are divided into 1 treatment group

Sponsors and collaborators